The unexpected discovery may provide scientists with new insights into how cancer develops — and how to combat it.

Discontinuing tyrosine kinase inhibitor maintenance after extended complete molecular response should only be attempted as part of a clinical trial, the researchers say.

Halting the relentless march of so-called 'zombie cells' that drive aging and age-related diseases could be a step closer ...

“Understanding how the repertoire of immune cells fits with the diverse landscape of brain cancer types can help us find new ...

In addition to exporting materials out of the nucleus, the protein, called Exportin-1 (also called Xpo1 or Crm1), seems to play a role in promoting gene transcription, the process that creates RNA ...

Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.

Identifying the JAK2V617F mutation has improved understanding of what causes overproduction of red blood cells, platelets, ...

Researchers from Northwestern University have stumbled upon a previously unobserved function of a protein found in the cell ...

Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and ...

Cognitive impairment is common in untreated MS patients, affecting 1 in 4, with rates particularly higher in those with SPMS, ...